Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein may spot hidden pregnancy danger

NCT ID NCT07421180

Diagnosis Sponsor: Adana City Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a substance in the blood called adropin can help identify placenta accreta spectrum, a serious condition where the placenta grows too deeply into the womb. Researchers measured adropin levels in 84 pregnant women—42 with the condition and 42 healthy—to see if it could serve as a diagnostic marker. The goal is to find a simple blood test that could warn doctors early, improving safety for mothers and babies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

84 people

The number who actually took part.

Started

May 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pregnant women aged 18-45 years in the reproductive period with singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS were included in the study. The control group consisted of healthy pregnant women in the third trimester with similar demographic characteristics who underwent elective cesarean delivery and had no obstetric or medical comorbidities.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women aged 18-45 years in the reproductive period * Singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS Exclusion Criteria: * Uterine anomalies, * Chronic systemic diseases, * Multiple pregnancies, * Obstetric complications such as preterm premature rupture of membranes, threatened preterm labor, fetuses followed for intrauterine growth restriction, and placental abruption.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Placenta accreta spectrum are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

placenta accreta placenta praevia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Placenta accreta spectrum Placenta previa

Contacts and locations

Locations

  • University of Heath and Science Adana City Hospital

    Adana, Yuregir, 01100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.